Merck & Co (MRK) Stock Price, Quote, News & History | Benzinga

Merck & Co Inc (MRK) Stock Price, Quote, News & History

MRKNYSE

Trade with Public

Trade with Public

$152.29

3.302.21%

Last update: Aug 21, 2:01 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Dividends Compare Options Stock Report

Key Statistics

Open

$149.12

Close

-

Volume / Avg.

8.73M / 10.70M

Day Range

$148.59 - $154.49

52 Wk Range

77.58 - 153.50

Market Cap

$375.73B

P/E Ratio

119.19

Dividend Yield

2.28%

Exchange

NYSE

RSI

77

Short Interest

1.15%

Days to Cover

3.25

Recent Merck & Co Inc News

If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now

Moderna stock soars on recent Phase 3 trial results. A look back at the company's IPO and the stock's ups and downs since.

Chris Katje

COVID-19 Made Moderna Famous: Cancer Could Define Its Future

Moderna's Phase 3 cancer vaccine breakthrough could mark a turning point as the biotech company looks to move beyond its COVID-era identity.

Surbhi Jain

QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History

Moderna closed up 176.97% on first-ever Phase 3 win for an mRNA cancer vaccine, then gave back as much as a quarter of it the next day.

Piero Cingari

Why Iovance Biotherapeutics Stock Hit 52-Week High

Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.

Vandana Singh

Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche (CORRECTED)

Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine, raising stakes for BioNTech & Genentech's program.

Surbhi Jain

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

19.97B

Investing Cash Flow (TTM)

-27.30B

Financing Cash Flow (TTM)

6.17B

Free Cash Flow (TTM)

16.06B

Capital Expenditure (TTM)

-3.90B

Net Change in Cash (TTM)

-1.16B

Analyst Trends and Forecast

2

Apr

1

1

May

2

Jun

6

2

Jul

7

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$414.35B

PE Ratio (TTM)

119.19

PE Ratio (FWD)

54.05

PEG Ratio (TTM)

14.26

PS Ratio (TTM)

5.55

PB Ratio (TTM)

8.77

Earnings Yield % (TTM)

0.84%

Earnings Yield % (FWD)

1.85%

EV / EBITDA (TTM)

28.76

Price / EBITDA (TTM)

25.66

Price / Free Cash Flow (TTM)

23.02

Book Value / Share

$17.00

Company Debt

Total Debt

$53.91B

LT Debt

$51.08B

LT Debt Issuance (TTM)

$19.84B

LT Debt Repayment (TTM)

-$1.15B

Total Cash

$6.85B

Debt to Equity

1.29

Issuance of Debt (TTM)

$18.69B

Repayment of Debt (TTM)

-$7.15B

Key Statistics

Open

$149.12

Close

-

Volume / Avg.

8.73M / 10.70M

Day Range

$148.59 - $154.49

52 Wk Range

77.58 - 153.50

Market Cap

$375.73B

P/E Ratio

119.19

Dividend Yield

2.28%

Exchange

NYSE

RSI

77

Short Interest

1.15%

Days to Cover

3.25

About

Sector

Health Care

Industry

Pharmaceuticals

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to ov...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Merck & Co (MRK) stock?

A

You can purchase shares of Merck & Co (NYSE:MRK) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Merck & Co (MRK) competitors?

A

Other companies in Merck & Co’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), AstraZeneca PLC (NYSE:AZN) and Novo Nordisk AS (NYSE:NVO).

Q

What is the forecast, or price target, for Merck & Co (MRK) stock?

A

Merck & Co has a consensus price target of $136.26.

Q

What is the current price for Merck & Co (MRK)?

A

The stock price for Merck & Co (NYSE: MRK) is $152.29 last updated August 21, 2026 at 2:01 PM EDT.

Q

Does Merck & Co (MRK) pay a dividend?

A

There are no upcoming dividends for Merck & Co.

Q

When is Merck & Co (NYSE:MRK) reporting earnings?

A

Merck & Co does not have any upcoming earnings scheduled.

Q

Is Merck & Co (MRK) going to split?

A

There is no upcoming split for Merck & Co.

Q

What sector and industry does Merck & Co (MRK) operate in?

A

Merck & Co is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.